Q-omics provides the consensus-scored RHAG profile across patient tissues and cancer cell-line models. RHAG expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RHAG is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, RHAG protein abundance shows 11,819 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight THCA, and CCRCC as cancer lineages where RHAG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHAG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHAG survival associations across molecular data types. RHAG RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHAG RNA expression–survival associations across cancer types. High RHAG expression shows unfavorable associations in THCA, SCLC, TGCT, LUAD, KIRP and LUSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RHAG RNA expression.
This table summarizes RHAG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RHAG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHAG shows lower tumor expression in THCA, COAD, READ, BLCA, BRCA and STAD. The THCA box plot shows higher RHAG RNA expression in normal versus tumor tissue (log2 FC = −0.142, t-test p < 0.001).
This table shows molecular features associated with RHAG in patient tissues and cancer cell lines. In patient samples, RHAG shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHAG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
